Document is current

Article History

Received: 27 February 2020

Accepted: 20 July 2020

First Online: 24 September 2020

Competing interests

: Dr. Linge is involved in an ongoing publicly funded (German Federal Ministry of Education and Research) Project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). For the present manuscript, Dr. Linge confirms that this above mentioned funding source was not involved. Dr. Richter received individual funding as lecturer from Siemens Healthineers (2018). OncoRay has institutional research agreements with Siemens Healthineers. Furthermore, OncoRay has an institutional agreement as reference center for dual-energy CT in radiotherapy as well as a software evaluation contract with Siemens Healthineers. In the past 5 years, Dr. Krause received funding for her research Projects by IBA (2016), Merck KGaA (2014–2018 for preclinical study; 2018-2020 for clinical study), Medipan GmbH (2014–2018). In the past 5 years, Dr. Troost, Dr. Krause and Dr. Löck have been involved in an ongoing publicly funded (German Federal Ministry of Education and Research) Project with the companies Medipan, Attomol GmbH, GA Generic Assays GmbH, Gesellschaft für medizinische und wissenschaftliche genetische Analysen, Lipotype GmbH and PolyAn GmbH (2019–2021). For the present manuscript, none of the above mentioned funding sources were involved. In the past 5 years, Dr. Baumann attended an advisory board meeting of MERCK KGaA (Darmstadt), for which the University of Dresden received a travel grant. He further received funding for his research Projects and for educational grants to the University of Dresden by Teutopharma GmbH (2011–2015), IBA (2016), Bayer AG (2016–2018), Merck KGaA (2014–2030), Medipan GmbH (2014-2018). For the German Cancer Research Center (DKFZ, Heidelberg) Dr. Baumann is on the supervisory boards of HI-STEM gGmbH (Heidelberg). Dr. Baumann, as former chair of OncoRay (Dresden) and present CEO and Scientific Chair of the German Cancer Research Center (DKFZ, Heidelberg), was or is responsible for collaborations with a multitude of companies and institutions, worldwide. In this capacity, he has signed/signs contracts for his institute(s) and for the staff for research funding and/or collaborations with industry and academia, worldwide. In this role, he was/is further responsible for commercial technology transfer activities of his institute(s), including patent and other similar IP portfolios. Dr. Baumann confirms that none of the above funding sources were involved in the preparation of this paper. University Department of Radiation Oncology Tübingen receives financial and technical support from Elekta AB (Stockholm, Sweden) under a research agreement. The other authors have nothing to disclose.